quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·31d
PRRelease
BridgeBio Pharma Inc. logo

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

BBIO· BridgeBio Pharma Inc.
Health Care
Original source

Companies

  • BBIO
    BridgeBio Pharma Inc.
    Health Care

Recent analyst ratings

  • Apr 9UpdateRBC Capital Mkts$100.00
  • Mar 10UpdateWilliam Blair-
  • Jan 28UpdateBarclays$157.00
  • Jan 6UpdateMorgan Stanley$96.00
  • Dec 11UpdateBernstein$94.00
  • Jul 30UpdateRaymond James$56.00

Related

  • PR1d
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
  • SEC7d
    Amendment: SEC Form SCHEDULE 13G/A filed by BridgeBio Pharma Inc.
  • INSIDER10d
    SEC Form 4 filed by Kumar Neil
  • SEC14d
    SEC Form 144 filed by BridgeBio Pharma Inc.
  • ANALYST14d
    RBC Capital Mkts initiated coverage on BridgeBio Pharma with a new price target
  • SEC21d
    Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.
  • SEC24d
    BridgeBio Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR24d
    Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022